Dendreon appoints John Johnson to aid recovery
This article was originally published in Scrip
Following Dendreon's recent share price crash (scripintelligence.com, 4 August 2011), the company has appointed John Johnson, CEO of Savient Pharmaceuticals, to its board of directors. Mr Johnson’s earlier corporate history saw him serve as CEO of Imclone during a period of global growth before Lilly acquired the company for $6.5 billion.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.